Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Cosmetic Protocol

Acetyl Hexapeptide-3 (Argireline)Complete Dosing & Administration Guide

SNARE complex inhibitor that reduces expression wrinkles through topical neuromuscular modulation — the 'Botox in a bottle' peptide.

Dose Range

5%-10%%

Frequency

Once daily

Route

Topical

Cycle Length

Ongoing/indefinite

Dosing

How much
do I take?

Timing

Best time to take

Apply Acetyl Hexapeptide-3 (Argireline) to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption, unless otherwise directed.

With food?

As a topical product, Acetyl Hexapeptide-3 (Argireline) is not affected by food intake. Apply to clean skin and allow adequate absorption time before covering the area.

If stacking

Acetyl Hexapeptide-3 (Argireline) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting Your Dose

Increase if

  • +You've tolerated the current dose for the recommended period without significant side effects
  • +Therapeutic goals haven't been met at the current dose level
  • +Your healthcare provider recommends dose escalation based on your response
  • +Lab work or clinical assessments support a higher dose

Decrease if

  • -Side effects are bothersome or impacting daily life despite management strategies
  • -You experience any signs of an adverse reaction
  • -Lab results indicate the need for dose reduction
  • -Your healthcare provider recommends a lower dose based on your response

Signs of right dose

  • Therapeutic goals being met with minimal side effects
  • Stable and consistent response to treatment
  • Lab values or clinical markers trending in the right direction
  • Good tolerance with manageable or absent side effects

Dosing Calculator

Calculate Your Exact Dose

1
2
3
4

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The weight is on the label

Peptide vial
5mg

Select Weight

mg

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

Administration

How do I
use it?

Reconstitution

What you need

  • Acetyl Hexapeptide-3 (Argireline) in its prescribed form
  • Clean, dry storage container
  • Measuring device if applicable (oral syringe, measuring cup)
  • Calendar or reminder app for dosing schedule

Example

Acetyl Hexapeptide-3 (Argireline) comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.

Use Acetyl Hexapeptide-3 (Argireline) exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.

Injection

Route

Acetyl Hexapeptide-3 (Argireline) is administered Topical—no injection required

Best sites

  • Not applicable—this is not an injectable formulation

Technique

  • 1.Follow the specific administration instructions for your Acetyl Hexapeptide-3 (Argireline) formulation
  • 2.Take or apply as directed by your healthcare provider
  • 3.Store properly between uses according to package instructions

Storage

Before reconstitution

Store Acetyl Hexapeptide-3 (Argireline) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, Acetyl Hexapeptide-3 (Argireline) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation

  • Solution appears cloudy, discolored, or contains visible particles (should be clear)
  • Product has been exposed to temperatures outside the recommended storage range
  • Product has been frozen (unless specifically designed for freeze-thaw stability)
  • Expiration date has passed or reconstituted solution has exceeded its use-by date
  • Unusual odor, color change, or visible contamination

Sample Daily Schedule

As prescribed (once daily)

As prescribed by your healthcare provider injection

Site: Topical—rotate sites if applicable

Maintain a consistent schedule for optimal results with Acetyl Hexapeptide-3 (Argireline). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is it
safe?

Safety Profile

Acetyl Hexapeptide-3 demonstrates an excellent safety profile for topical cosmetic use with no serious adverse events reported in clinical studies. At the 10% concentrations used in cosmetic formulations, systemic absorption is minimal and no neurotoxicity has been observed despite its mechanism of action on the neuromuscular junction. The peptide shows a safety margin of approximately 100-fold compared to toxic reference compounds. Primary concerns are limited to local skin irritation in sensitive individuals, such as mild erythema, transient stinging, or contact dermatitis in those with peptide hypersensitivity.

Evidence comes from multiple clinical studies demonstrating safety at cosmetic concentrations, including 4-week dermatological safety trials showing no systemic toxicity or significant adverse effects. The mechanism of action is well-characterized in vitro and validated through efficacy studies. Data suggests the peptide's large molecular size and poor transepidermal penetration provide a natural safety barrier, preventing systemic effects even with prolonged topical use.

Common Side Effects

Experienced by some users

Mild Skin Irritation

Rare mild irritation in sensitive individuals, typically during initial use. Generally self-resolving.

Management: Start with once daily application. If persistent, reduce concentration or discontinue.

Transient Redness

Temporary redness at application site, particularly on thin or sensitive periorbital skin.

Management: Patch test before full application. Allow skin to acclimate over first few days.

Slight Dryness

Minor dryness when peptide solution is used without adequate moisturization in dry environments.

Management: Always follow with a hydrating moisturizer or use Argireline in a cream-based formulation.

Stinging on Compromised Skin

Brief stinging if applied to areas where skin barrier is disrupted (after exfoliation or sun exposure).

Management: Avoid application on freshly exfoliated or sunburned skin. Wait for barrier recovery before use.

Less Common

  • Contact Dermatitis

These typically resolve with continued use or dose adjustment.

Stop and Seek Help If

  • ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • ×Your healthcare provider recommends discontinuation based on your clinical response
  • ×Development of any new medical condition that may be contraindicated with Acetyl Hexapeptide-3 (Argireline)
  • ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • ×Abnormal lab results or clinical markers that suggest adverse effects

Acetyl Hexapeptide-3 (Argireline) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Interactions

With other peptides

  • May be used together under medical guidance.
  • May be used together under medical guidance.
  • May be used together under medical guidance.

With medications

  • !Vitamin C at Very Low pH (<3.5) - Use with caution—discuss with your healthcare provider.
  • !Benzoyl Peroxide - Use with caution—discuss with your healthcare provider.
  • !Strong AHA/BHA Peels - Use with caution—discuss with your healthcare provider.

With supplements

  • Multivitamins - Generally safe to take alongside Acetyl Hexapeptide-3 (Argireline). Space doses apart if taking oral formulations to ensure optimal absorption.
  • Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Want the Full Picture?

View the complete Acetyl Hexapeptide-3 (Argireline) research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.

View Full Acetyl Hexapeptide-3 (Argireline) Profile

Medical Disclaimer

Acetyl Hexapeptide-3 (Argireline) is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: 2/8/2026